Certainly one of the key lessons learned has been not only to look at the pieces about forecasting and about which products we should be stocking in this strategic stockpile, but also the domestic biomanufacturing piece.
The domestic biomanufacturing piece is an important one, because we continue to procure from different domestic manufacturers. I was mentioning earlier that 100% of face shields are procured from a domestic manufacturer. We have 50% of surgical masks that are procured by the Public Health Agency, and these are domestically manufactured. We have others that are N95 respirators.
We have been working with ISED, PSPC and other colleagues in the federal family, as well as with stakeholders, to make sure we have the appropriate kinds of both equipment and PPE sourced from domestic suppliers. That constitutes a major part of our stockpile.